Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.

CONCLUSIONS: Silencing of cyclin D1 combined with olaparib may lead to substantial benefit for ovarian cancer management by mimicking a BRCAness phenotype, and induction of G0/G1 cell cycle arrest.
PMID: 30414739 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - November 7, 2018 Category: Cancer & Oncology Authors: Zhong Q, Hu Z, Li Q, Yi T, Li J, Yang H Tags: Gynecol Oncol Source Type: research